Therapeutic Area

Pain Management

Therapeutic area intelligence for Pain Management with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 5
Catalysts: 0
Companies: 1

Companies

Pacira Pharmaceuticals →

Assets

Anesthesia →

Hospira →

Recent signals(5)

ClinicalJune 21, 2026

Study Compares Iovera Cryoneurolysis to Radiofrequency Ablation for Chronic Low Back Pain

A clinical trial is underway to evaluate the efficacy of the iovera° system against radiofrequency ablation for chronic low back pain.

ClinicalJune 20, 2026

Study on Liposomal Bupivacaine for Pain Management in VATS Partial Pneumonectomy

A clinical trial is evaluating the effectiveness of intercostal nerve block with liposomal bupivacaine versus conventional bupivacaine in improving postoperative recovery quality in VATS partial pneumonectomy.

RegulatoryJune 9, 2026

FDA Grants AP Status for Lidocaine Hydrochloride 0.4% in Dextrose 5%

The FDA has granted Abbreviated Approval (AP) status for Lidocaine Hydrochloride 0.4% in Dextrose 5% submitted by Hospira.

RegulatoryJune 9, 2026

FDA Approval Status Update for Lidocaine Hydrochloride 0.4% in Dextrose 5%

The FDA has granted an approval status (AP) for ANDA083158, a supplemental application for Lidocaine Hydrochloride 0.4% in Dextrose 5% submitted by Hospira.

ClinicalJune 2, 2026

Comparative Study of SPSIPB vs Thoracic Paravertebral Block for Opioid Reduction

This clinical trial aims to compare the analgesic efficacy of Serratus Posterior Superior Intercostal Plane Block and Thoracic Paravertebral Block in reducing postoperative opioid consumption after open thoracotomy.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.